About Overactive Bladder (OAB) Therapeutics
Overactive bladder (OAB) is a syndrome that manifests complex symptoms such as urinary urgency with or without urinary incontinence accompanied by increased frequency and nocturia. The disease is more prevalent in women than in men, and the prevalence rate is directly proportional to age, i.e., the prevalence rate of OAB increases with the increase in age. Global OAB therapeutics market is currently dominated by anticholinergic agents, which exert its pharmacologic effect by inhibiting the neurotransmitter acetylcholine in the central and peripheral nervous system. However, the on-going research in new areas such as gene therapy can lead to change in the treatment landscape, going forward.
Technavio’s analysts forecast the global Overactive Bladder (OAB) Therapeutics market to grow at a CAGR of 1.56% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global Overactive Bladder (OAB) Therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Overactive Bladder (OAB) Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Allergan
• Astellas Pharma
• Hisamitsu Pharmaceutical
• Pfizer
Other prominent vendors
• Ferring
• GlaxoSmithKline
• Ion Channel Innovations
• Kwang Dong Pharmaceutical
• Lanzhou Institute of Biological Products
• Merck
• ONO Pharmaceutical
• Sanofi
• Tengion
• Teva Pharmaceutical Industries
Market driver
• Growing geriatric population
• For a full, detailed list, view our report
Market challenge
• Rise in economic burden of OAB
• For a full, detailed list, view our report
Market trend
• Advancing biomedical science
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Market outline
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Pipeline analysis
PART 07: Market segmentation based on drug class
Management of OAB
Anticholinergic agents
Beta-3-adrenoreceptor agonists
Others
PART 08: Drug profile of key OAB therapeutics
TOVIAZ
VESIcare
Betanis/Myrbetriq/BETMIGA
PART 09: Geographical segmentation
OAB therapeutics market in Americas
OAB therapeutics market in EMEA
OAB therapeutics market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
Market drivers
Market challenges
PART 12: Market trends
Advancing biomedical science
Advent of novel drug delivery systems
Gene therapy in OAB
PART 13: Vendor landscape
Competitive scenario
PART 14: Key vendor analysis
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Other prominent vendors
PART 15: Appendix
List of abbreviations
List of Exhibits
Exhibit 01: Prevalence rate of OAB in women aged under 25 years versus women aged over 65 years
Exhibit 02: OAB pathophysiology
Exhibit 03: Global OAB therapeutics market snapshot
Exhibit 04: Global OAB therapeutics market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis of global OAB therapeutics market
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline molecules at various developmental stage
Exhibit 08: Pipeline molecules arranged as per drug class
Exhibit 09: Key clinical trials
Exhibit 10: Purpose of key clinical trials
Exhibit 11: Segmentation of global OAB therapeutics market by drug class 2016
Exhibit 12: Global OAB therapeutics market share by drug class, 2016
Exhibit 13: Global OAB therapeutics market segmentation by drug class 2016
Exhibit 14: Global OAB anticholinergic therapeutics market 2016-2021 ($ millions)
Exhibit 15: Types of ACh receptors
Exhibit 16: Mechanism of action of MRA
Exhibit 17: Global OAB beta-3 adrenoreceptor agonists market 2016-2021 ($ millions)
Exhibit 18: Mechanism of action of mirabegron
Exhibit 19: Global OAB therapeutics market for others 2016-2021 ($ millions)
Exhibit 20: TOVIAZ year-over-year (YoY) revenue 2010-2016 ($ millions)
Exhibit 21: VESIcare revenue in different regions in 2015-2016 ($ millions)
Exhibit 22: Betanis/Myrbetriq/BETMIGA revenue in different regions 2015-2016 ($ millions)
Exhibit 23: Betanis/Myrbetriq/BETMIGA patents
Exhibit 24: History of drug approvals in OAB
Exhibit 25: Segmentation of global OAB therapeutics market by geography 2016 and 2021
Exhibit 26: Global OAB therapeutics market revenue by geography 2016-2021 ($ millions)
Exhibit 27: Global OAB therapeutics market share by geography 2016-2021 (%)
Exhibit 28: Global OAB therapeutics market scenario in different regions
Exhibit 29: Market scenario in Americas
Exhibit 30: OAB therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 31: Prevalence rate of OAB in US 2007
Exhibit 32: Market scenario in EMEA
Exhibit 33: OAB therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 34: Market scenario in APAC
Exhibit 35: OAB therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 36: Probability of continuing antimuscarinic treatment in patients depending on their age
Exhibit 37: Geriatric population analysis by geography 2000 and 2030 (estimated) (in millions)
Exhibit 38: Prevalence rate of OAB in different age groups in Finland 2003-2004 (%)
Exhibit 39: OAB-POLL survey in US adults 2010
Exhibit 40: Telephonic interview evaluating the treatment outcomes with antimuscarinic agents in OAB patients
Exhibit 41: Competitive structure analysis of global OAB therapeutics market 2016
Exhibit 42: Allergan: Key highlights
Exhibit 43: Allergan: Strength assessment
Exhibit 44: Allergan: Strategy assessment
Exhibit 45: Allergan: Opportunity assessment
Exhibit 46: Astellas Pharma: Key highlights
Exhibit 47: Astellas Pharma: Strength assessment
Exhibit 48: Astellas Pharma: Strategy assessment
Exhibit 49: Astellas Pharma: Opportunity assessment
Exhibit 50: Hisamitsu Pharmaceutical: Key highlights
Exhibit 51: Hisamitsu Pharmaceutical: Strength assessment
Exhibit 52: Hisamitsu Pharmaceutical: Strategy assessment
Exhibit 53: Hisamitsu Pharmaceutical: Opportunity assessment
Exhibit 54: Pfizer: Key highlights
Exhibit 55: Pfizer: Strength assessment
Exhibit 56: Pfizer: Strategy assessment
Exhibit 57: Pfizer: Opportunity assessment
